Published DateClear

Start Date

End Date

Category

• Pipeline2

Organizations

• Bausch + Lomb70
• Eyes On Eyecare54
• Alcon, Inc.49
• American Optometric Association38
• Harrow32
• Glaukos30
• Topcon Healthcare26
• Regeneron25
• Aldeyra Therapeutics21
• Genentech19

Tags

• FDA2
• Rosah Syndrome2
• Clinical Trials2
• Retina1

• Organizations: Drug Farm✕

Clear all

Pipeline

FDA grants Fast Track designation for Drug Farm's ROSAH syndrome asset

Status enables expedited regulatory review process for DF-003, designed to target the genetic root cause of this rare genetic disease.

Pipeline

Drug Farm receives FDA IND clearance for ROSAH syndrome candidate

ALPK1 selective kinase inhibitor is the first therapeutic to target the genetic cause of this rare disease.